PIDD has previously been described as a death domain (DD)-containing protein that is inducible upon p53 activation and plays a role in programmed cell death. It has previously been shown that PIDD interacts with RAIDD (RIP-associated ICE/CED3 homologous protein with a death domain) in a cytoplasmic complex known as the PIDDosome, which results in the activation of capsase-2 and ultimately in cell death in response to DNA damage. Despite earlier studies on PIDD, however, the physiological role of PIDD has not been elucidated. Thus, we have generated PIDD-deficient mice and examined its in vivo functions particularly in cell death and in antiviral innate immunity. The first major aim of the thesis is to determine whether or not PIDD is required in cell death. PIDD mice are developmentally normal and do not display a pronounced phenotype. Surprisingly, PIDD deficiency perturbed neither DNA damage-induced nor stress-induced cell death in a variety of cell types, suggesting that PIDD may not play a critical role in cell death. In addition, caspase-2 processing occurred normally in the absence of PIDD in response to ionizing irradiation or etoposide treatment, indicating that PIDD is dispensable in the cleavage of caspase-2. The second major aim is to examine the role of PIDD and RAIDD in LCMV-induced innate immunity. To study the role of PIDD and RAIDD in antiviral immune responses, I have generated PIDD/RAIDD double-deficient mice and challenged them with lymphocytic choriomeningitis virus (LCMV). Interestingly, I observed that ablation of both PIDD and RAIDD together resulted in defective viral clearance in the spleen, but not in other organs including the lung, liver, and kidney. In addition, the production of type I IFN was also decreased in the mice deficient in both PIDD and RAIDD. However, the cytotoxicity of the T lymphocytes was largely intact in the absence of both PIDD and RAIDD. Collectively, our results suggest that PIDD is dispensable in cell death, yet PIDD and RAIDD together have a synergistic effect in LCMV-induced antiviral innate immunity. The findings presented in this thesis provide a better understanding of the physiological role of PIDD and may ultimately contribute to the novel therapeutic strategies for the proper control of viral infection.

Expression studies have implicated Fibronectin Leucine Rich Transmembrane protein 2 (FLRT2) in cranial neural crest cell migration and pre-chondrogenic cell condensation during craniofacial skeletogenesis. This aim of this study was to characterize the expression of FLRT2 and its relationship to the extracellular matrix (ECM) in ATDC5 chondroprogenitor cells. Immunofluorescence studies localized FLRT2 to the cell membrane as well as exracellularly, where it colocalized with fibronectin. FLRT2 was identified in the ATDC5-derived ECM after cell extraction. Further to its colocalization with fibronectin, FLRT2 associated with fibronectin-coated beads in cell cultures. Co-immunoprecipitation confirmed that FLRT2 and fibronectin interact, either directly or indirectly. Blocking fibronectin fibril formation in ATDC5 cell cultures demonstrated a concomitant decrease in extracellular FLRT2 accumulation. It appears that FLRT2 may exist in both a membrane-bound and a shed form. Either or both of these forms may participate in cell-ECM interactions in cooperation with fibronectin or other ECM proteins.

Expression studies have implicated Fibronectin Leucine Rich Transmembrane protein 2 (FLRT2) in cranial neural crest cell migration and pre-chondrogenic cell condensation during craniofacial skeletogenesis. This aim of this study was to characterize the expression of FLRT2 and its relationship to the extracellular matrix (ECM) in ATDC5 chondroprogenitor cells. Immunofluorescence studies localized FLRT2 to the cell membrane as well as exracellularly, where it colocalized with fibronectin. FLRT2 was identified in the ATDC5-derived ECM after cell extraction. Further to its colocalization with fibronectin, FLRT2 associated with fibronectin-coated beads in cell cultures. Co-immunoprecipitation confirmed that FLRT2 and fibronectin interact, either directly or indirectly. Blocking fibronectin fibril formation in ATDC5 cell cultures demonstrated a concomitant decrease in extracellular FLRT2 accumulation. It appears that FLRT2 may exist in both a membrane-bound and a shed form. Either or both of these forms may participate in cell-ECM interactions in cooperation with fibronectin or other ECM proteins.

Urofacial syndrome (UFS; MIM# 236730) is a rare autosomal recessive condition characterised by urinary bladder and bowel voiding dysfunction with a pathognomonic abnormality of facial movement with expression. UFS can be caused by biallelic putative loss-of-function mutations in HPSE2, which encodes heparanase 2. Failure to discover HPSE2 mutations in all cases of UFS suggests genetic heterogeneity. The urinary tract features of UFS overlap those seen in the spectrum of non-syndromic non-neurogenic voiding dysfunction and vesicoureteric reflux (VUR). This overlap suggests there may be some aspects of pathogenesis in common. The project aimed to define the genotypic and phenotypic spectrum associated with mutations in HPSE2 by Sanger sequencing and multiplex ligation-dependent probe amplification (MPLA) in newly referred cases of UFS and making comparison to a review of mutations and phenotypes seen in the literature. This work discovered five further families with HPSE2 associated UFS increasing known mutations whilst, reinforced that this is an under-recognised condition and emphasised the previously under-reported feature of facial weakness. The failure to discover HPSE2 mutations in all cases referred provided further evidence of genetic heterogeneity. The project also aimed to discover further genes associated with UFS. Autozygosity mapping and whole exome sequencing was carried out in cases of UFS without mutations in HPSE2. This led to the recognition that UFS is also caused by biallelic putative loss-of-function mutations in LRIG2 encoding the leucine-rich repeats and immunoglobulin-like domains 2 (LRIG2) protein in three families. Failure to identify LRIG2 mutations in all HPSE2 negative families suggests further genetic heterogeneity. To address the question of whether the pathogenesis of UFS overlaps more common conditions with a similar spectrum of urinary tract abnormalities I aimed to examine whether pathogenic variants in HPSE2 and LRIG2 were seen in these phenotypes. Unexpectedly this led to the discovering of further families affected by UFS but failed to show an association of variants in UFS genes with non-syndromic urinary tract abnormalities. However, variants of potential interest were discovered. As part of work toward understanding the pathogenesis of UFS and designing a model to test the pathogenesis of sequence variants expression studies in a Xenopus tropicalis hpse2 knock-down model of UFS were carried out. The knock-down model provided valuable insight in to the likely pathogenesis of UFS with evidence pointing towards a congenital peripheral neuropathy with failure of correct nerve path finding. Understanding the pathogenesis of UFS has the potential to direct further research in to therapeutic intervention.

As proteínas que contem domínios ricos em leucina (LRR) mediam interações macromoleculares que estão envolvidas em muitos processos biológicos como infecção bacteriana em células hospedeiras e respostas imunológicas de plantas. Estudos anteriores em nosso laboratório identificaram um gene que codifica uma proteína contendo 6 LRRs (LaLRR17) em L. (L.) amazonensis. O LaLRR17 é um gene com expressão estágio regulada sendo abundantemente expresso na fase amastigota. Seqüências homólogas ao gene LaLRR17 foram encontradas em todas as espécies de Leishmania analisadas. Esse trabalho tem como objetivo a caracterização da proteína homóloga em L. (L.) major (LmLRR17). Anticorpos obtidos contra seqüências conservadas das proteínas LaLRR17 e LmLRR17 permitiram o estudo da abundância protéica em diferentes estágios do parasita. Curiosamente, a proteína LmLRR17 foi encontrada em maior abundância em promastigotas procíclicos em vez de amastigotas. Linhagens hiperexpressoras da proteína LmLRR17 ou expressoras da proteína LaLRR17 em fusão com o epitopo viral myc foram obtidas. As proteínas quiméricas foram expressas seguindo o mesmo padrão observado na cepa selvagem. O fenótipo desses mutantes foi avaliado mediante infecções de macrófagos in vitro. A hiperexpressão da proteína LmLRR17 em L. (L.) major não alterou o fenótipo da infecção in vitro. Por outro lado, a expressão da proteína heteróloga, LaLRR17, em promastigotas de L. (L.) major levou a incremento na virulência com maior número de células infectadas e de parasitas por célula. Esses resultados indicam que a expressão da proteína LmLRR17 em L. (L.) major é fortemente regulada. Esse trabalho também mostra que a expressão da proteína LaLRR17 em L. (L.) major leva a um aumento na infectividade. / Proteins containing leucine rich repeats (LRR) are known to be involved in macromolecular interactions in many processes such as signal transduction, cell-adhesion, RNA processing, apoptosis, disease resistance and immune response. A previous study in our laboratory identified a L. (L.) amazonensis gene encoding a protein containing 6 LRRs (LaLRR17). LaLRR17 is a stage-regulated gene expressed with increased abundance in the amastigote stage. Highly conserved homologues of LaLRR17 were found in all Leishmania species analyzed. Therefore, the aim of this study was to characterize the homologous protein of L. major (LmLRR17). Antibodies raised against peptide sequences common to LaLRR17 and LmLRR17 allowed the study of the steady-state protein abundance. Interestingly, LmLRR17 protein was found to be up-regulated in procyclic promastigotes, instead of amastigotes. Mutants of L. (L.) major overexpressing a myc-tagged version of LmLRR17 or of LaLRR17 protein were obtained. In these parasites, the chimeric proteins were expressed following the same pattern of expression observed in the wild type parasites. The phenotype of these mutants was assessed in vitro through macrophage infections. Overexpression of LmLRR17 protein in L. (L.) major resulted in an unaltered phenotype. On the other hand, overexpression of LaLRR17 in L. (L.) major induced an increase in virulence with a higher number of infected cells and intracellular parasites. These results indicate that the expression of LmLRR17 protein in L. major is tightly regulated and the expression of the heterologous LaLRR17 protein increased infectivity in vitro.

As proteínas que contem domínios ricos em leucina (LRR) mediam interações macromoleculares que estão envolvidas em muitos processos biológicos como infecção bacteriana em células hospedeiras e respostas imunológicas de plantas. Estudos anteriores em nosso laboratório identificaram um gene que codifica uma proteína contendo 6 LRRs (LaLRR17) em L. (L.) amazonensis. O LaLRR17 é um gene com expressão estágio regulada sendo abundantemente expresso na fase amastigota. Seqüências homólogas ao gene LaLRR17 foram encontradas em todas as espécies de Leishmania analisadas. Esse trabalho tem como objetivo a caracterização da proteína homóloga em L. (L.) major (LmLRR17). Anticorpos obtidos contra seqüências conservadas das proteínas LaLRR17 e LmLRR17 permitiram o estudo da abundância protéica em diferentes estágios do parasita. Curiosamente, a proteína LmLRR17 foi encontrada em maior abundância em promastigotas procíclicos em vez de amastigotas. Linhagens hiperexpressoras da proteína LmLRR17 ou expressoras da proteína LaLRR17 em fusão com o epitopo viral myc foram obtidas. As proteínas quiméricas foram expressas seguindo o mesmo padrão observado na cepa selvagem. O fenótipo desses mutantes foi avaliado mediante infecções de macrófagos in vitro. A hiperexpressão da proteína LmLRR17 em L. (L.) major não alterou o fenótipo da infecção in vitro. Por outro lado, a expressão da proteína heteróloga, LaLRR17, em promastigotas de L. (L.) major levou a incremento na virulência com maior número de células infectadas e de parasitas por célula. Esses resultados indicam que a expressão da proteína LmLRR17 em L. (L.) major é fortemente regulada. Esse trabalho também mostra que a expressão da proteína LaLRR17 em L. (L.) major leva a um aumento na infectividade. / Proteins containing leucine rich repeats (LRR) are known to be involved in macromolecular interactions in many processes such as signal transduction, cell-adhesion, RNA processing, apoptosis, disease resistance and immune response. A previous study in our laboratory identified a L. (L.) amazonensis gene encoding a protein containing 6 LRRs (LaLRR17). LaLRR17 is a stage-regulated gene expressed with increased abundance in the amastigote stage. Highly conserved homologues of LaLRR17 were found in all Leishmania species analyzed. Therefore, the aim of this study was to characterize the homologous protein of L. major (LmLRR17). Antibodies raised against peptide sequences common to LaLRR17 and LmLRR17 allowed the study of the steady-state protein abundance. Interestingly, LmLRR17 protein was found to be up-regulated in procyclic promastigotes, instead of amastigotes. Mutants of L. (L.) major overexpressing a myc-tagged version of LmLRR17 or of LaLRR17 protein were obtained. In these parasites, the chimeric proteins were expressed following the same pattern of expression observed in the wild type parasites. The phenotype of these mutants was assessed in vitro through macrophage infections. Overexpression of LmLRR17 protein in L. (L.) major resulted in an unaltered phenotype. On the other hand, overexpression of LaLRR17 in L. (L.) major induced an increase in virulence with a higher number of infected cells and intracellular parasites. These results indicate that the expression of LmLRR17 protein in L. major is tightly regulated and the expression of the heterologous LaLRR17 protein increased infectivity in vitro.